Burlington’s EmpowerPharm is Canada’s first ever pharmaceutical facility licensed to fabricate merchandise containing marijuana.
Well being Canada granted the native firm a Drug Institution Licence (DEL) on Monday, the primary in additional than 4 a long time for a brand new Canadian-owned firm that has constructed a facility for prescription medication.
Having beforehand obtained a Hashish Drug Licence, a Customary Processing Licence and a Hashish Analysis Licence, EmpowerPharm now finds itself compliant with Good Manufacturing Apply (GMP) requirements.
Scientific trials are presently underway to advance Empower CBD(tm), a brand new cannabidiol-based prescription drugs indicated for anxiousness that may be prescribed beneath the path of a certified doctor.
Cannabidiol is a chemical within the Hashish sativa plant, often known as marijuana or hemp.
At present not one of the hashish merchandise available on the market used for anxiousness are accredited as prescription medicines by Well being Canada.
Canadians are going through a spike in anxiousness as a consequence of COVID-19 with the results anticipated to be felt for years, in keeping with the Canadian Psychological Well being Fee.
EmpowerPharm, which features a state-of-the-art $30 million manufacturing facility, was established in 2018 by Aubrey Dan and Peter Billiaert.
Collectively Dan and Billiaert have over 55 years of expertise within the pharmaceutical business.